Macquarie Group’s Phibro Animal Health PAHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,060
Closed -$21K 2012
2022
Q3
$21K Sell
1,060
-539
-34% -$9.31K ﹤0.01% 2185
2022
Q2
$31K Hold
1,599
﹤0.01% 2184
2022
Q1
$32 Hold
1,599
﹤0.01% 2281
2021
Q4
$33K Hold
1,599
﹤0.01% 2281
2021
Q3
$34K Hold
1,599
﹤0.01% 2336
2021
Q2
$46K Hold
1,599
﹤0.01% 2175
2021
Q1
$39K Sell
1,599
-636
-28% -$14.4K ﹤0.01% 2136
2020
Q4
$43K Hold
2,235
﹤0.01% 2077
2020
Q3
$39K Hold
2,235
﹤0.01% 2009
2020
Q2
$59K Sell
2,235
-1,975
-47% -$49K ﹤0.01% 1892
2020
Q1
$102K Sell
4,210
-3,990
-49% -$97.5K ﹤0.01% 1632
2019
Q4
$204K Hold
8,200
﹤0.01% 1601
2019
Q3
$175K Hold
8,200
﹤0.01% 1614
2019
Q2
$261K Buy
+8,200
New +$257K ﹤0.01% 1526
2019
Q1
Sell
-431
Closed -$14K 1934
2018
Q4
$14K Sell
431
-200
-32% -$7.55K ﹤0.01% 1869
2018
Q3
$27K Sell
631
-9,367
-94% -$443K ﹤0.01% 1838
2018
Q2
$460K Buy
9,998
+1,400
+16% +$62K ﹤0.01% 1384
2018
Q1
$341K Buy
8,598
+3,107
+57% +$115K ﹤0.01% 1519
2017
Q4
$184K Sell
5,491
-2,300
-30% -$81.7K ﹤0.01% 1753
2017
Q3
$289K Buy
+7,791
New +$293K ﹤0.01% 1632

Other funds holding PAHC

Macquarie Group's PAHC Position: Q4 2022 in Review

Macquarie Group sold out of Phibro Animal Health (PAHC) in Q4 2022, closing a stake of 1,060 shares — an estimated $21K sold.

Macquarie Group first reported a position in PAHC in Q3 2017 and held it in 20 quarters. The position peaked at $460K in Q2 2018. 132 funds tracked by Wall St. Rank hold PAHC as of Q4 2022.

  • Macquarie Group reported no remaining Phibro Animal Health position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 1,060 Phibro Animal Health shares in Q4 2022, an estimated $21K.
  • Macquarie Group first reported a position in Phibro Animal Health in Q3 2017 and held it in 20 quarters.
  • Macquarie Group's Phibro Animal Health position peaked at $460K in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Phibro Animal Health as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.